Why Johnson & Johnson Stock Popped on Friday

Johnson & Johnson (NYSE: JNJ) banal jumped 3.4% done 12:20 p.m. ET Friday aft Guggenheim expert Vamil Divan raised his terms people connected the already buy-rated banal to $270 per share.

Johnson & Johnson banal closed beneath $245 yesterday, suggesting Divan sees imaginable for the biopharmaceutical institution to summation different 10.2% implicit the adjacent 12 months. Add a 2.2% dividend yield, and that's a respectable 12.4% imaginable nett successful a year.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Why Guggenheim loves Johnson & Johnson banal

Divan updated his numbers up of JNJ's Q2 net merchandise owed July 15. Going implicit the numbers, helium predicts humble top- and bottom-line "beats" for the company, with gross coming successful astir $25.5 cardinal and profits of possibly $2.87 per share.

On guidance, Divan advises investors to absorption connected 2 cardinal areas for JNJ: immunology and oncology. On the former, Tremfya, Caplyta, and Erleada prescriptions are doing amended than expected, and he's reasoning this inclination could continue, particularly for Tremfya (an anti-inflammatory).

In oncology, the names to ticker are Darzalex, Carvykti, Tecvayli, and Talvey, arsenic good arsenic the much precocious launched Inlexzo and SQ Rybrevant (for bladder crab and non-small compartment lung cancer, respectively). Johnson & Johnson's beardown cause portfolio leads Divan to telephone it his "Top Pick" successful large-cap biopharma.

How risky is Johnson & Johnson stock?

Despite a humble terms people and beardown cause prospects, though, and I'm not definite I hold connected that -- due to the fact that of the valuation. JNJ banal trades astatine much than 28 times earnings, but astir analysts forecast lone a single-digit net maturation complaint implicit the adjacent 5 years.

Strong escaped currency travel mightiness assistance to alteration my mind, but successful fact, JNJ's escaped currency travel looks comparatively anemic astatine lone astir 85% of reported earnings.

I don't spot Johnson & Johnson banal arsenic overmuch of a bargain.

Should you bargain banal successful Johnson & Johnson close now?

Before you bargain banal in Johnson & Johnson, see this:

The Motley Fool Stock Advisor analyst squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Johnson & Johnson wasn't 1 of them. The 10 stocks that made the chopped are built for semipermanent maturation and could nutrient monster returns successful the coming years.

Consider when Netflix made this database connected December 17, 2004... if you invested $1,000 astatine the clip of our recommendation, you'd person $382,359!* Or when Nvidia made this database connected April 15, 2005... if you invested $1,000 astatine the clip of our recommendation, you'd person $1,201,390!*